Balchem Corporation reports developments tied to its specialty ingredient manufacturing business for health, nutrition, agriculture, healthcare, and other industrial markets. The company operates through Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products, with recurring updates on segment sales, earnings, cash flow, debt, share repurchases, and conference participation.
Company news also includes product and market developments such as customized food and beverage ingredient systems, key nutrients for food, supplement, and pharmaceutical applications, animal nutrition products, choline chloride, specialty-packaged chemicals, and chelated minerals for micronutrient agriculture. Updates have included the Metalosate® T.E.A.M.™ plant tissue analysis platform and trade actions affecting choline chloride supply chains.
Balchem (BCPC) will participate in Baird’s Global Industrial Conference on November 11, 2026, with members of its leadership team. Participants will include Chairman, President and Chief Executive Officer Ted Harris, Chief Financial Officer Martin Bengtsson, and Senior Director Investor Relations Allison Baurichter.
Balchem (NASDAQ: BCPC) reported third-quarter 2026 net sales of $290.7 million, with sales and operating earnings growing across all three reporting segments. Sales rose 8.6% year over year, while GAAP net earnings increased 16.0% to $46.7 million. Diluted earnings per share reached $1.46 versus $1.24 a year earlier. Adjusted EBITDA, a non-GAAP earnings measure, rose 12.4% to $80.3 million.
Human Nutrition and Health sales increased 8.1%, Animal Nutrition and Health sales rose 11.7%, and Specialty Products sales grew 4.5%. Gross margin expanded to 36.4% from 35.7%, despite certain higher manufacturing input costs. Operating expenses increased to $43.3 million from $40.9 million. Operating cash flow was $69.8 million and free cash flow was $57.9 million. Balchem made $28.0 million in net debt payments during the quarter. Nine-month sales reached $845.364 million, versus $773.544 million a year earlier.
Balchem (BCPC) will hold a conference call on October 23, 2026, to review its third quarter 2026 financial results. The call begins at 11:00 AM Eastern Time, hosted by Chairman, President and CEO Ted Harris and CFO Martin Bengtsson. Results will be published before the market opens that day, with the release and financial exhibits available on the company website before the call.
Balchem Corporation (BCPC) will participate in the 9th Annual Wells Fargo Consumer Conference on September 23, 2026. Chairman, President and CEO Ted Harris, CFO Martin Bengtsson and Senior Director of Investor Relations Allison Baurichter are scheduled to attend and represent the company.
Balchem (NASDAQ: BCPC) reported record second quarter 2026 results, with net sales of $284.0 million, up 11.2% year over year, GAAP net earnings of $44.6 million (+16.6%), adjusted EBITDA of $77.9 million (+12.6%), and free cash flow of $36.2 million.
GAAP EPS was $1.39 versus $1.17 and adjusted EPS was $1.49 versus $1.27 in the prior-year quarter. All three segments delivered higher sales: Human Nutrition and Health $176.9 million (+10.0%), Animal Nutrition and Health $64.5 million (+15.0%), and Specialty Products $40.5 million (+8.9%). Consolidated gross margin rose 11.4% to $103.7 million, with margin at 36.5%.
Balchem amended its revolving credit facility on July 24, 2026, extending maturity to July 24, 2031 and increasing borrowing capacity from $550 million to $650 million. The company repurchased $29 million of stock in Q2 and $114 million over the trailing twelve months, ended the quarter with net debt of $88.8 million and a net leverage ratio of 0.3x.
Balchem (NASDAQ: BCPC) will hold a quarterly conference call on Friday, July 31, 2026, at 11:00 AM ET to review its second quarter 2026 financial results. The company will release the results and financial exhibits before the market opens and post them on its website.
Institutional investors, analysts, and the public can join via dial-in or a live webcast, with a replay available online for one year.
Balchem (NASDAQ:BCPC), a global specialty ingredient manufacturer serving health and nutrition markets, announced participation in the CJS Securities 26th Annual New Ideas Summer Conference on July 9, 2026. Ted Harris, Martin Bengtsson, and Allison Baurichter are scheduled to represent the company.
Balchem (NASDAQ:BCPC), a global specialty ingredient manufacturer for health and nutrition markets, will participate in the Wells Fargo Industrials Conference on June 10, 2026.
Chairman, President and CEO Ted Harris, CFO Martin Bengtsson, and Senior Director Investor Relations Allison Baurichter are scheduled to attend.
Balchem (NASDAQ: BCPC) reported Q1 2026 results for the quarter ended March 31, 2026: net sales $270.7M, GAAP net earnings $40.3M, adjusted EBITDA $74.3M, and free cash flow $33.8M. Gross margin rose to $101.1M (37.3% of sales). Company reported record Q1 sales, adjusted EBITDA, and net earnings, with growth across all three segments.
Cash balance was $72.9M; net debt $96.1M; dividend paid $30.8M and share repurchases $15.7M. A published clinical study using VitaCholine appears in Nutrients. Quarterly call scheduled April 30, 2026 at 11:00 AM ET.
Balchem (NASDAQ: BCPC) published its 2025 Sustainability Report on April 22, 2026, highlighting environmental and social progress. Key metrics: a 31% absolute reduction in Scope 1 and Scope 2 emissions vs 2020 (surpassing a 25% 2030 target), 16% water withdrawal reduction vs 2020, and external limited assurance for select emissions data.
The report notes alignment with the UN Global Compact, that ~75% of revenue supports specific UN SDGs, more than half of facilities have five+ consecutive injury-free years, and completion of double materiality and climate risk assessments.